Tìm theo
CMC-544
Thuốc Gốc
Biotech
CMC544 is an antibody-cytotoxic conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia.
Cơ Chế Tác Dụng : CMC544 is an antibody-cytotoxic conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. CMC-544 is a CD22-targeted immunoconjugate of calicheamicin and exerts a potent cytotoxic effect against CD22+ B-cell lymphoma. CMC-544 is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora. CMC-544 confers strong therapeutic activity against systemic disseminated B-cell lymphoma.
Chỉ Định : Investigated for use/treatment in cancer/tumors (unspecified) and lymphoma (non-hodgkin's).
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05889
Wikipedia
http://en.wikipedia.org/wiki/Inotuzumab_ozogamicin
... loading
... loading